Cite

    Alison J Moskowitz et al.. “PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.” Lancet oncology, vol. 16, no. 3, n.d., pp. 284–292. http://access.bl.uk/ark:/81055/vdc_100026002943.0x00002b